Low Leverage / Balance Sheet StrengthZero reported debt is a durable balance-sheet strength: it lowers refinancing pressure and interest burden, increases financial flexibility to fund R&D or scale operations, and reduces bankruptcy risk, giving the company runway to execute on tech commercialization despite current losses.

Improving Revenue TrendA 22% YoY revenue increase in 2025 indicates renewed commercial traction and demand for the platform. Sustained top-line growth helps absorb fixed costs over time, supports scaling economics, and is a prerequisite for eventual margin improvement if the company converts early wins into repeatable sales.

Strong Strategic Market PositionThe core acoustofluidic platform addresses structural growth markets (cell therapy and bioprocessing) with label-free continuous-flow separation. Specialized technology aligned with durable industry demand can create differentiated product-market fit and long-term commercial opportunity if adoption continues.

Bears Say

Sustained Operating LossesMulti-year operating losses and negative EBIT/EBITDA show the business is not yet profitable. Persistent unprofitability drains capital, delays self-sufficiency, and increases reliance on external financing, making the path to sustainable margins and shareholder returns uncertain over the medium term.

Weak Cash GenerationNegative operating cash flow in recent years indicates the core operations do not generate sufficient cash. This structural cash burn elevates funding risk, increases likelihood of dilutive equity raises or costly financing, and constrains the firm’s ability to invest consistently in commercialization and R&D.

Reliance On Equity Funding / Fluctuating EquitySignificant year-to-year equity fluctuations imply recurring capital raises. Dependence on equity financing can dilute existing shareholders, signal limited internal cash generation, and create execution risk if markets tighten, complicating long-term planning and investor returns over several quarters.

4SA FAQ

What was AcouSort AB’s price range in the past 12 months?

AcouSort AB lowest stock price was €0.12 and its highest was €0.32 in the past 12 months.

What is AcouSort AB’s market cap?

AcouSort AB’s market cap is €6.24M.

When is AcouSort AB’s upcoming earnings report date?

AcouSort AB’s upcoming earnings report date is May 27, 2026 which is in 68 days.

How were AcouSort AB’s earnings last quarter?

AcouSort AB released its earnings results on Feb 25, 2026. The company reported -€0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.011.

Is AcouSort AB overvalued?

According to Wall Street analysts AcouSort AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AcouSort AB pay dividends?

AcouSort AB does not currently pay dividends.

What is AcouSort AB’s EPS estimate?

AcouSort AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AcouSort AB have?

AcouSort AB has 21,163,902 shares outstanding.

What happened to AcouSort AB’s price movement after its last earnings report?

AcouSort AB reported an EPS of -€0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 63.584%.

Which hedge fund is a major shareholder of AcouSort AB?

Currently, no hedge funds are holding shares in DE:4SA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AcouSort AB

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.